The International Workshop on Chronic Lymphocytic Leukemia has updated its 2008 consensus guidelines for design and conduct of CLL clinical trials.
The incidence of Merkel cell carcinoma, an aggressive neuroendocrine skin cancer, has grown rapidly since the disease was first described in 1972.
During the NCCN Annual Conference in Orlando, Dr. Peter Carroll from UCSF discussed the evolution of screening tests for prostate cancer.
PARP inhibitors are offering new treatment options for ovarian cancer patients with known mutations, but early-stage diagnosis is still elusive.
Interventions can improve sun protection behaviors, but this does not necessarily correlate with skin cancer/melanoma outcomes, according to a review for the USPSTF.
Medicial oncologist and melanoma expert Dr. Jeffrey Weber discusses the role of adjuvant immunotherapy in the setting of stage III melanoma.
Protecting Breast Cancer Patients From Cardiac Adverse Effects of Treatment With Anthracyclines and HER2-Targeted Therapies
During the 2018 Miami Breast Cancer Conference, cardiologist Dr. Jean-Bernard Durand discussed protecting patients who are being treated with anthracyclines and HER2-targeted therapies from serious cardiac adverse events.
Recent FDA approval of front-line brentuximab vedotin with chemotherapy in patients with stage III/IV Hodgkin lymphoma offers the first new treatment for this disease in over 40 years.
ASTRO has released new guidelines recommending hypofractionated whole-breast irradiation for women with breast cancer.
A recent phase III study revealed a benefit with pacritinib for patients with myelofibrosis and thrombocytopenia who have experienced treatment failure with previous therapies.
The FDA is granting Priority Review for the expanded use of enzalutamide in nonmetastatic castration-resistant prostate cancer.
Should a patient with fallopian tube cancer undergo genetic risk evaluation? What is essential in post-treatment monitoring of ovarian, fallopian tube, and primary peritoneal cancers? Take this multiquestion quiz to find out.
Differential methylation in CITED4, as measured in blood, appears to be a promising marker of bladder cancer susceptibility in women.
At the 2018 Miami Breast Cancer Conference, Dr. Patrick Borgen presented information related to gene expression profiling as a tool for managing DCIS.
A registry study suggests that there may be a familial association between ovarian and testicular cancers.